Cancer Genetics Inc (CGIX)

1.82
0.03 1.60
NASDAQ : Health Care
Prev Close 1.85
Open 1.90
Day Low/High 1.76 / 1.90
52 Wk Low/High 1.82 / 11.45
Volume 181.69K
Avg Volume 97.90K
Exchange NASDAQ
Shares Outstanding 16.12M
Market Cap 28.37M
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cancer Genetics, Inc. And ApoCell Announce Partnership Focused On Transforming Cancer Profiling & Therapy Selection Leveraging Proprietary, High-Performance, Liquid Biopsy Platform For Rare Cell Capture And Detection

Cancer Genetics, Inc. And ApoCell Announce Partnership Focused On Transforming Cancer Profiling & Therapy Selection Leveraging Proprietary, High-Performance, Liquid Biopsy Platform For Rare Cell Capture And Detection
Cancer Genetics, Inc. To Present At Two Upcoming Investor Conferences During September

Cancer Genetics, Inc. To Present At Two Upcoming Investor Conferences During September
Cancer Genetics, Inc. Announces A Global Partnership With BARC Global Central Laboratory To Offer Comprehensive Clinical Trial And Companion Diagnostic Solutions For The Oncology Industry

Cancer Genetics, Inc. Announces A Global Partnership With BARC Global Central Laboratory To Offer Comprehensive Clinical Trial And Companion Diagnostic Solutions For The Oncology Industry

Cancer Genetics Announces $5.5 Million Registered Direct Offering

Cancer Genetics Announces $5.5 Million Registered Direct Offering

Cancer Genetics, Inc. To Present At The Rodman & Renshaw 18th Annual Global Investment Conference

Cancer Genetics, Inc. To Present At The Rodman & Renshaw 18th Annual Global Investment Conference

Cancer Genetics, Inc. Strengthens Position As A Leader In Myeloid Cancer Diagnosis And Management Receiving New York State Approval For Focus::Myeloid™, A Targeted NGS Panel For Improved Diagnosis, Risk Stratification, And Therapy Selection Of Patients With Myeloid Cancers

Cancer Genetics, Inc. Strengthens Position As A Leader In Myeloid Cancer Diagnosis And Management Receiving New York State Approval For Focus::Myeloid™, A Targeted NGS Panel For Improved Diagnosis, Risk Stratification, And Therapy Selection Of Patients With Myeloid Cancers

Cancer Genetics, Inc. Reports Second Quarter 2016 Financial Results And Provides Company Updates

Cancer Genetics, Inc. Reports Second Quarter 2016 Financial Results And Provides Company Updates

Cancer Genetics To Report Second Quarter Earnings On Wednesday, August 10

Cancer Genetics To Report Second Quarter Earnings On Wednesday, August 10

Cancer Genetics Inc. Selected By H3 Biomedicine Inc., To Provide Biomarker Discovery And Testing For A Global Drug Development Program In Hematologic Cancers

Cancer Genetics Inc. Selected By H3 Biomedicine Inc., To Provide Biomarker Discovery And Testing For A Global Drug Development Program In Hematologic Cancers

Cancer Genetics, Inc. Receives New York State Approval For Focus::CLL™, A Unique NGS Panel For Chronic Lymphocytic Leukemia, Reinforcing The Company's Market-Leading Position In The Diagnosis And Management Of B-Cell Cancers

Cancer Genetics, Inc. Receives New York State Approval For Focus::CLL™, A Unique NGS Panel For Chronic Lymphocytic Leukemia, Reinforcing The Company's Market-Leading Position In The Diagnosis And Management Of B-Cell Cancers

Cancer Genetics, Inc. Expands Its Immuno-Oncology Franchise With The Addition Of The FDA-Approved VENTANA PD-L1 (SP142) Assay As A Complementary Diagnostic Test For TECENTRIQ™

Cancer Genetics, Inc. Expands Its Immuno-Oncology Franchise With The Addition Of The FDA-Approved VENTANA PD-L1 (SP142) Assay As A Complementary Diagnostic Test For TECENTRIQ™

Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts As COO And Executive Vice President Of Finance

Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts As COO And Executive Vice President Of Finance

Cancer Genetics, Inc. And Sayre Therapeutics Announce Distribution Agreement To Commercialize CGI's Proprietary FDA-cleared Tissue Of Origin (TOO®) Test Throughout India And South Asia

Cancer Genetics, Inc. And Sayre Therapeutics Announce Distribution Agreement To Commercialize CGI's Proprietary FDA-cleared Tissue Of Origin (TOO®) Test Throughout India And South Asia

Cancer Genetics, Inc. To Present At The 2016 LD Micro Invitational Investor Conference

Cancer Genetics, Inc. To Present At The 2016 LD Micro Invitational Investor Conference

Cancer Genetics Announces $5 Million Registered Direct Offering

Cancer Genetics Announces $5 Million Registered Direct Offering

Cancer Genetics, Inc. Launches The Most Comprehensive & Clinically Actionable Next Generation Sequencing Panel In Precision Medicine, FOCUS::Lymphoma ™

Cancer Genetics, Inc. Launches The Most Comprehensive & Clinically Actionable Next Generation Sequencing Panel In Precision Medicine, FOCUS::Lymphoma ™

The Panel Provides Critical Genomic Information To Improve Patient Management & Guide Therapy Decisions

Cancer Genetics, Inc. Announces 39% Revenue Increase And Provides Recent Company Highlights

Cancer Genetics, Inc. Announces 39% Revenue Increase And Provides Recent Company Highlights

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades.

Cancer Genetics, Inc. To Present At Pioneers 2016 Conference Presented By Joseph Gunnar & Co., LLC

Cancer Genetics, Inc. To Present At Pioneers 2016 Conference Presented By Joseph Gunnar & Co., LLC

Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech And Pharma Companies

Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech And Pharma Companies

Cancer Genetics To Report First Quarter 2016 Financial Results On Tuesday, May 10th

Cancer Genetics To Report First Quarter 2016 Financial Results On Tuesday, May 10th

Insider Trading Alert - CGIX, SAVE And BRKS Traded By Insiders

Insider Trading Alert - CGIX, SAVE And BRKS Traded By Insiders

Stocks with insider trader activity include CGIX, SAVE and BRKS

Insider Trading Alert - MAC, PNM And CGIX Traded By Insiders

Insider Trading Alert - MAC, PNM And CGIX Traded By Insiders

Stocks with insider trader activity include MAC, PNM and CGIX

Cancer Genetics, Inc. To Present At 28th Annual ROTH Conference On March 16, 2016

Cancer Genetics, Inc. To Present At 28th Annual ROTH Conference On March 16, 2016

7 Stocks Under $10 Making Big Moves Higher

7 Stocks Under $10 Making Big Moves Higher

These under-$10 stocks are within range of triggering breakout trades. Here's how to trade them from here.

Cancer Genetics, Inc. Announces Strong Fourth Quarter And Full-Year 2015 Results And Provides 2016 Business Update

Cancer Genetics, Inc. Announces Strong Fourth Quarter And Full-Year 2015 Results And Provides 2016 Business Update

Cancer Genetics, Inc. Launches Next Generation Sequencing Panel For Diagnosis & Treatment Selection In Solid Tumors, CGI FOCUS::Oncomine™

Cancer Genetics, Inc. Launches Next Generation Sequencing Panel For Diagnosis & Treatment Selection In Solid Tumors, CGI FOCUS::Oncomine™

Cancer Genetics To Report Fourth Quarter & Fiscal 2015 Financial Results On Thursday, March 10

Cancer Genetics To Report Fourth Quarter & Fiscal 2015 Financial Results On Thursday, March 10

Cancer Genetics, Inc. To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

Cancer Genetics, Inc. To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

Cancer Genetics, Inc. Expands The Reach Of Precision Medicine By Over 2.6 Million Individuals As It Signs A New Agreement With Blue Cross Blue Shield Of Minnesota

Cancer Genetics, Inc. Expands The Reach Of Precision Medicine By Over 2.6 Million Individuals As It Signs A New Agreement With Blue Cross Blue Shield Of Minnesota

Load More
Quant Rating on 2:16 PM EDT 9/27/2016

D-

(Sell)

From Our Partners

Cancer Genetics initiated with a Buy at Rodman & Renshaw
The Fly

Cancer Genetics inks direct placement of 2.75M shares of stock at $2; shares off 2% premarket
SeekingAlpha

The Good, Bad, And Ugly Of SWK Holdings
SeekingAlpha

Healthcare - Top 5 Gainers / Losers as of 11:00 am
SeekingAlpha

Cancer Genetics beats by $0.05, beats on revenue
SeekingAlpha

Notable earnings before Wednesday’s open
SeekingAlpha

Cancer Genetics downgraded to Neutral from Buy at Janney Capital
The Fly

Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks

Cancer Genetics (CGIX) Looks Good: Stock Gains 7.2% - Tale of the Tape
Zacks

Cancer Genetics (CGIX) Shows Strength: Stock Gains 5.8% - Tale of the Tape
Zacks

Cancer Genetics initiated with a Buy at Janney Capital
The Fly

Cancer Genetics, Inc. (CGIX) in Focus: Stock Jumps 5.3% - Tale of the Tape
Zacks
Stocks you follow Edit
Authors you follow Edit
My Reading List
save an article here

Trending
The 10 States Most Reliant on Federal Dollars
'Pretty Surprised' at Number of Twitter (TWTR) Suitors, Mizuho Analyst Says
5 Stocks Set to Soar on Bullish Earnings
Why GoPro (GPRO) Stock Is Falling Today
Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results